Latest Sunesis Pharmaceuticals (SNSS) Headlines
Post# of 53
Posted On: 03/13/2014 2:41:01 AM
Latest Sunesis Pharmaceuticals (SNSS) Headlines
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 06, 6:09AM CST
Phase 1b/2 Data From MD Anderson Sponsored Study of Vosaroxin in AML and
Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:25AM CST
Sunesis was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences;
Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2013.
Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Feb 27, 8:53AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0 million. Net proceeds are expected to be approximately $40.0 million, after deducting the underwriting discount and estimated offering expenses payable by Sunesis. If exercised in full, the warrants could result in additional net financing proceeds to Sunesis of $95.3 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions.
Sunesis Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Feb 26, 3:14PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Small Cap Biotechs Developing Novel Cancer Treatments
George Budwell, The Motley Fool - Motley Fool - Tue Feb 18, 1:30PM CST
Cancer drugs can be game-changers for their developers because of their comparatively high margins and their tendency to be applicable to a broad array of disease states. In short, Foolish investors would be wise to keep an eye out for companies...
Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 7:58AM CST
Sunesis Pharmaceuticals saw a big move last session, as the company’s shares fell by over 5% on the day
Sunesis (SNSS) Catches Eye: Stock Soars 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:25AM CST
Sunesis was a big mover last session, with shares surging over 18%.
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
GlobeNewswire - Mon Feb 10, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of Joseph I. DePinto to the newly created position of Executive Vice President and Chief Commercial Officer. Mr. DePinto brings over two decades of experience in global commercial operations, including the leadership of the commercial, marketing and strategic development efforts behind a number of prominent oncology products.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 07, 5:24PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:23AM CST
Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy?
Lupus LA/Cedars-Sinai Rheumatology Fellowship Program Names Dr. Vaneet Sandhu As Fellow
PR Newswire - Thu Jan 30, 6:00AM CST
Lupus LA and Cedars-Sinai Medical Center have joined together to support a two-year fellowship and have named Dr. Vaneet Sandhu as the Lupus LA/Cedars-Sinai Fellow. Lupus is a chronic autoimmune disease that can affect virtually any organ of the body, and has no known cause or cure. Dr. Sandhu will be joining a 'dream team' of lupus researchers at Cedars-Sinai, known in the medical community for cutting edge research and world-renowned patient care. The Lupus LA/Cedars-Sinai Rheumatology Fellowship was funded by Lupus LA.
OvaScience (OVAS) in Focus: Stock Tumbles 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:34AM CST
OvaScience stock tumbles 8% yesterday, continuing the recent downtrend
Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
at The Street - Fri Jan 17, 2:52PM CST
The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.
Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs
GlobeNewswire - Thu Jan 09, 5:59AM CST
BTK Inhibitor SNS-062 Licensed from Biogen Idec;
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 06, 6:09AM CST
Phase 1b/2 Data From MD Anderson Sponsored Study of Vosaroxin in AML and
Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:25AM CST
Sunesis was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences;
Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2013.
Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Feb 27, 8:53AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0 million. Net proceeds are expected to be approximately $40.0 million, after deducting the underwriting discount and estimated offering expenses payable by Sunesis. If exercised in full, the warrants could result in additional net financing proceeds to Sunesis of $95.3 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions.
Sunesis Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Feb 26, 3:14PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Small Cap Biotechs Developing Novel Cancer Treatments
George Budwell, The Motley Fool - Motley Fool - Tue Feb 18, 1:30PM CST
Cancer drugs can be game-changers for their developers because of their comparatively high margins and their tendency to be applicable to a broad array of disease states. In short, Foolish investors would be wise to keep an eye out for companies...
Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 7:58AM CST
Sunesis Pharmaceuticals saw a big move last session, as the company’s shares fell by over 5% on the day
Sunesis (SNSS) Catches Eye: Stock Soars 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:25AM CST
Sunesis was a big mover last session, with shares surging over 18%.
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
GlobeNewswire - Mon Feb 10, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of Joseph I. DePinto to the newly created position of Executive Vice President and Chief Commercial Officer. Mr. DePinto brings over two decades of experience in global commercial operations, including the leadership of the commercial, marketing and strategic development efforts behind a number of prominent oncology products.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 07, 5:24PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:23AM CST
Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy?
Lupus LA/Cedars-Sinai Rheumatology Fellowship Program Names Dr. Vaneet Sandhu As Fellow
PR Newswire - Thu Jan 30, 6:00AM CST
Lupus LA and Cedars-Sinai Medical Center have joined together to support a two-year fellowship and have named Dr. Vaneet Sandhu as the Lupus LA/Cedars-Sinai Fellow. Lupus is a chronic autoimmune disease that can affect virtually any organ of the body, and has no known cause or cure. Dr. Sandhu will be joining a 'dream team' of lupus researchers at Cedars-Sinai, known in the medical community for cutting edge research and world-renowned patient care. The Lupus LA/Cedars-Sinai Rheumatology Fellowship was funded by Lupus LA.
OvaScience (OVAS) in Focus: Stock Tumbles 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:34AM CST
OvaScience stock tumbles 8% yesterday, continuing the recent downtrend
Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
at The Street - Fri Jan 17, 2:52PM CST
The drug companies on this list issued the most ridiculous, stock-touting press releases, all seeking to glom onto the excitement of the JPM healthcare conference.
Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs
GlobeNewswire - Thu Jan 09, 5:59AM CST
BTK Inhibitor SNS-062 Licensed from Biogen Idec;
(0)
(0)Viracta Therapeutics Inc. (VIRX) Stock Research Links
Scroll down for more posts ▼